Longevity Vision Fund
VC Fund
New York, United States
Longevity Vision Fund is a $100M investment fund dedicated to making longevity affordable and accessible to all. The fund accelerates longevity breakthroughs by investing in companies that develop technologies, products, and services that extend healthy human lifespans and overcome the negative effects of agingLongevity Vision Fund provides Seedto Series C funding to biotech and life extension-focused companies that have demonstrated affordable longevity potential and vision of milestones driving up the value of the company and market validation.
- Total investments:
- 22
- Last investment:
- Lead investor:
- 5%
- Fund size:
- $50M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Longevity Vision Fund invests in
Stages Longevity Vision Fund invests in
Countries Longevity Vision Fund invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series B
- $37M–$230M
- Series C
- $65M–$300M
Investment Focus
Industry
- Biotechnology 13 (59%)
- Health Care 9 (41%)
- Medical 4 (18%)
- Biopharma 3 (14%)
- Medical Device 3 (14%)
Stage
- Series B 10 (45%)
- Series C 5 (23%)
- Series A 2 (9%)
- Seed 1 (5%)
- Debt Financing 1 (5%)
Country
- United States 12 (55%)
- Hong Kong 2 (9%)
- Isle of Man 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Avik Arakelian
Head of Investments
|
Head of Investments | Total investments: 0 | Find email | |
Sergey Young
Founder
|
Founder | Total investments: 2 | Find email | |
Sourav Sinha
Venture Partner & Head of Innovation
|
Venture Partner & Head of Innovation | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Senda Biosciences is a developer of therapeutic applications intended for novel treatments of human disease.The company studies the molecular relationships between bacterial, botanical, and human cells as well as how they define health and disease, providing medical professionals with novel medications and delivery methods.Senda Biosciences wasestablished in 2017 by David Kolesky, Ignacio Martinez, and John Casey in Cambridge, Massachusetts. | $123M / Series C / Aug 16, 2022 | ||
| Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine,building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability. | $300M / Series C / Apr 19, 2022 | ||
| Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $100M / Series B / Nov 02, 2021 | ||
| Laronde develops an eRNA-based therapeutic platform that is capable of indicating diverse proteins inside the body. It is persistent, non-immunogenic, allows for repeat dosing, and offers flexibility in formulation and delivery.Laronde was founded in 2017 by Flagship Labs, the innovation foundry of Flagship Pioneering. The company is rapidlyscaling to support the parallel development of multiple programs across many disease areas. | $440M / Series B / Aug 30, 2021 | ||
| Exo is a medical device startup handheld ultrasound platform and AI for imaging and therapeutic applications. The company is committed to delivering affordable and easy-to-use medical imaging to healthcare professionals around the world. By delivering easy-to-use, high-quality medical imaging. Exo empowers healthcare professionals to make critical,real-time decisions that improve patient outcomes.The Exo ultrasound platform combines advances in nano-materials, novel sensor technologies, advanced signal processing, and computation with the economies of scale of semiconductor manufacturing to dramatically reduce the cost of imaging. It also represents a giant leap in imaging and therapeutics technology one that will drive the development of high-performance products that are accessible, easy-to-use, and available at a price point never before possible. | $220M / Series C / Jul 29, 2021 | ||
| Senda Biosciences is a developer of therapeutic applications intended for novel treatments of human disease.The company studies the molecular relationships between bacterial, botanical, and human cells as well as how they define health and disease, providing medical professionals with novel medications and delivery methods.Senda Biosciences wasestablished in 2017 by David Kolesky, Ignacio Martinez, and John Casey in Cambridge, Massachusetts. | $98M / Series B / Jun 10, 2021 | ||
| Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine,building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability. | $230M / Series B / Jan 12, 2021 | ||
| Valo Health, LLC (Valo) is a technology company that is using human-centric data and machine learning-anchored computation to transform the drug discovery and development process. By integrating data across the drug development lifecycle, the discovery and development of life-changing treatments can be accelerated, with the potential to reducecost, time, and failure rate. The company's Opal Computational Platform™, a fully integrated, componentized, end-to-end drug development platform, offers a unique approach to therapeutic development, that enables Valo to advance a robust pipeline of candidates across cardiovascular disease, oncology, and neurodegeneration. | $190M / Series B / Jan 11, 2021 | ||
| LyGenesis is an organ regeneration company enabling a patient's own lymph nodes to be used as bioreactors to regrow functioning ectopic organs. Their initial target organ for clinical development is liver regeneration, with a focus on helping patients with end stage liver disease (ESLD). | $11M / Convertible Note / Dec 30, 2020 | ||
| Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detectearlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com. | $65M / Series C / Nov 09, 2020 | ||
| See all 22 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Longevity Vision Fund invest in?
Longevity Vision Fund invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series C stage. Most of the 22 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Longevity Vision Fund's check size?
Longevity Vision Fund typically joins rounds of $37M–$230M at Series B and $65M–$300M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Longevity Vision Fund participates in.
How do I contact Longevity Vision Fund?
Public channels for Longevity Vision Fund include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Longevity Vision Fund?
The team at Longevity Vision Fund includes Avik Arakelian (Head of Investments), Sergey Young (Founder) and Sourav Sinha (Venture Partner & Head of Innovation). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
